Clinical Trial Update: A Phase II, Cross-over Clinical Trial Evaluating the Efficacy and Safety of KVD900 (Sebetralstat) in the On-demand Treatment of Angioedema Attacks in Adult Subjects With Hereditary Angioedema Type I or II [Phase 2]

View source ↗

Summary

A Phase II cross-over study evaluating the efficacy and safety of KVD900 (Sebetralstat) for on-demand treatment of hereditary angioedema attacks in adults with …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hereditary Angioedema

Drugs mentioned

• KVD900 (Sebetralstat)

Snippet

Sponsor: KalVista Pharmaceuticals, Ltd. | Conditions: Hereditary Angioedema | Phase 2 | Status: COMPLETED | Results posted: 2023-02-08